Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
Get this in your inbox everyday by subscribing to our newsletters.
Teleflex yesterday priced $400 million worth of debt that the maker of surgical tools and equipment plans to use for debt refinancing.
The offering, of 4.875% senior notes due in 2026, is expected to close May 16. Teleflex said it plans call to use the money to refinance $393 million in debt under its revolving credit facility. J.P. Morgan and BofA Merrill Lynch are the joint book-runners for the flotation, Teleflex said. Read more
France’s Median Technologies is consolidating and expanding in Massachusetts, with a new Woburn facility set to open next week.
The medical imaging software maker and developer said the site will consolidate its existing operations in the Boston area, but also be big enough to handle an “ambitious U.S. recruitment plan.” Read more
Five months after spiking its plans for an initial public offering, EndoStim said today that it raised a $25 million Series D round for the neurostimulation device it’s developing to treat gastroesophageal reflux disease.
Saint Louis- and Nijmegen, Holland-based EndoStim said Endeavour Vision led the round, joined by existing backer Santé Ventures and new investors Wellington Partners and Gimv. Read more
Corvia Medical said today that it landed CE Mark approval in the European Union for its InterAtrial Shunt device for treating a type of heart failure.
The IASD is designed to lower blood pressure in the left atrium and lungs by creating a small opening between the left and right atria. It’s indicated for diastolic heart failure, also known as heart failure with preserved ejection fraction. Read more
Cardinal Health said today that its Cordis subsidiary is getting back into the drug-eluting stent game via an overseas distribution agreement with Biosensors International.
The deal calls for Cordis to sell the BioFreedom, BioMatrix NeoFlex, BioMatrix Alpha and Chroma stents made by Biosensors in Europe, the Middle East, Australia and New Zealand. Cordis said it plans to gradually roll out a new private-label brand for stents: Lumeno. Read more